Actively Recruiting
Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer
Led by European Institute of Oncology · Updated on 2026-03-24
30
Participants Needed
1
Research Sites
363 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Pilot study on circulating tumor DNA (ctDNA) in advanced/metastatic breast cancer with low levels of HER2 expression (HER2 low)
CONDITIONS
Official Title
Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with HER2-low breast cancer defined as IHC score 1+ or 2+ and not amplified by ISH test confirmed by local lab
- Breast cancer in advanced or metastatic stage before treatment
- Signed written informed consent before joining the study
- Accessible for follow-up visits during the study
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
European Institute of Oncology
Milan, MI, Italy, 20141
Actively Recruiting
Research Team
N
Nicola Fusco, MD
CONTACT
F
francesca lombardi, biologist
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here